Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health

15:18 EST 3 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Navidea Biopharmaceuticals (NYSE MKT: NAVB) announced today the completion of the sale to Cardinal Health (NYSE: CAH) of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to...

Other Sources for this Article

Navidea Biopharmaceuticals
Investors & Media
Jed Latkin, 614-973-7490
Interim COO & CFO


More From BioPortfolio on "Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...